Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06489041
Status
Recruiting
Apply to this trial

Conditions

  • Cancer
  • Gastrointestinal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx" — GENETIC
    Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.

Study Details

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Key Dates

Start date
Jul 18, 2025
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Other: Pharmacogenomic Testing
    A pharmacogenomic (PGx) microarray (multi-gene) panel will be performed to test for genetic variations in genes related to drug response.

Primary Outcome Measure

Number of potentially actionable results based on pharmacogenomic (PGx) test [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Atrium Health Levine CancerCharlotteNorth Carolina28204
Megan Lattanze
[email protected]
(980) 442-4239
Jai Patel, PharmD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlotte, NC

By research site
Atrium Health Levine Cancer· Charlotte, NC

Related Studies